Pacira Pharmaceuticals CFO Sells $1,494,450 in Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) CFO James S. Scibetta sold 15,000 shares of Pacira Pharmaceuticals stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $99.63, for a total value of $1,494,450.00. Following the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $498,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on PCRX. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $104.68.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.29% on Tuesday, hitting $102.23. The stock had a trading volume of 24,223 shares. Pacira Pharmaceuticals has a 52 week low of $35.53 and a 52 week high of $102.29. The stock’s 50-day moving average is $89.8 and its 200-day moving average is $76.95. The company’s market cap is $3.669 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. On average, analysts predict that Pacira Pharmaceuticals will post $-0.25 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.